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patients with tCDC developing CDAD are not clear.
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Piperacillin-
tazobactam;
Proton-pump
inhibitorshospitalized patients were obtained to detect fecal CDC. A polymerase chain reaction for tcdB
was performed to determine toxigenic isolates. CDAD was diagnosed if the patient had diar-
rhea and toxigenic C. difficile present in a stool sample.
Results: A total 483 patients with stool samples were eligible for the study. Eighty-six (17.8%)
patients had tCDC after screening, of whom 14 (16.3%) developed CDAD during follow-up.
Among those with tCDC, patients with subsequent CDAD were more likely to have diabetes
mellitus (p Z 0.01) and to have received piperacillinetazobactam (p Z 0.04), or proton-
pump inhibitors (PPIs; pZ 0.04) than those without developing CDAD. The variables were sta-
tistically significant as determined by multivariate analysis. However, the 60-day crude mortal-
ity rates among tCDC patients with and without subsequent development of CDAD were similar.
Conclusion: Diabetes mellitus and recent receipt of piperacillinetazobactam or PPIs are inde-
pendent risk factors for the development of CDAD among hospitalized patients with tCDC.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Clostridium difficile is a major cause of antibiotic-
associated diarrhea in hospitalized patients and causes a
variety of clinical manifestations, ranging from asymp-
tomatic carriage, infectious diarrhea, pseudomembranous
colitis, toxic megacolon, to death. The incidence of C.
difficile-associated diarrhea (CDAD) is increasingly recog-
nized worldwide.1e5 In Taiwan, the incidence of CDAD is
also increasing.6 The incidence of CDAD was 45 cases per
100,000 patient-days at the National Taiwan University
Hospital in 2010, a tertiary hospital in northern Taiwan,7
and 42.6 cases per 100,000 patient-days at the National
Cheng Kung University Hospital in 2007e2008, a tertiary
hospital in southern Taiwan.6
The risk factors for CDAD include antimicrobial exposure,
advanced age, prior hospitalization, use of feeding tubes,
gastrointestinal surgery,5 and the use of proton-pump in-
hibitors (PPIs). Most classes of antibiotic exposure have been
linked to CDAD, particularly third-generation cephalospo-
rins, clindamycin, or fluoroquinolones. Besides antibiotic
exposure, we had identified fecal C. difficile colonization
(CDC) as a risk factor for CDAD.8 We found that the preva-
lence of toxigenic C. difficile colonization (tCDC) among
hospitalized patients was 16.7%, of whom 17.9% developed
CDAD.8 Michelle et al also showed 20% of initial asymptom-
atic carriers of toxigenic C. difficile isolates developed CDAD
during follow-up.9 Asymptomatic C. difficile carriers also
had higher rates of skin (61% vs. 19%) and environmental (59%
vs. 24%) contamination than did noncarriers.9 C. difficile
could be identified from a variety of surfaces in the hospital
environment,10 whichmight play a role in the transmission of
C. difficile. Thus, CDC may be a significant issue in control-
ling the spread of C. difficile in hospital settings.
The reported prevalence of CDC varied in different
populations, such as 7.6% in healthy adults,11 0.6-10% in
hospitalized patients, and 51% in long-term care residents.9
In the limited literature, the risk factors for CDC were
similar to those of CDAD, including previous antibiotic
exposure10,12 and a history of CDAD.9 The most commonly
identified offending antibiotics were cephalosporins and
fluoroquinolones.10,12 Our previous study reported the
exposure of more than one class of antibiotics wasassociated with CDC.8 Besides antibiotics exposure, Loo
et al found previous hospitalization, use of chemotherapy,
PPIs, or H2 blockers, and the presence of antibodies against
toxin B at the time of admission, were risk factors for
healthcare-associated CDC.3
However, the variables predisposing the patients with
CDC to develop CDAD are not clear. Settle et al showed that
66% of patients with CDC would have CDAD as they had
received cefotaxime or piperacillinetazobactam. However,
it is not clear if their colonized C. difficile isolates were
toxigenic or nontoxigenic.13 The aim of our study was to
identify the risk factors of development of CDAD in hospi-
talized patients with tCDC.Materials and methods
We performed a prospective study at a medical ward of
Tainan Hospital, Department of Health, Executive Yuan, a
district hospital in southern Taiwan. From January 2011
to June 2012, those older than 18 years old with an
expected hospital stay for more than 5 days were enrolled
in the present study, which included the participants in
our earlier study.8 We excluded patients who had a history
of CDC or CDAD within 3 months, received metronidazole
or vancomycin therapy within 3 months, had a colectomy
or no stool obtained within 48 hours of admission, or had
CDAD or fecal colonization or infection due to Clostridium
species other than C. difficile at the time of
admission.14e16 The study was approved by the Institu-
tional Review Board of Tainan Hospital and signed informed
consent forms were obtained from all patients.
The stool samples were obtained from patients less than
48 hours after admission, weekly during hospitalization,
and at the onset of diarrhea. If the patient was readmitted,
the stool samples were collected again and repeated every
week during hospitalization. Stool samples were plated on
cycloserineecefoxitinefructose agar, transferred into the
anaerobic chamber within less than 1 hour after collection,
and incubated for 48 hours. Isolates were confirmed to be
C. difficile on the basis of typical odor, appearance of
colonies, and specific biochemical reactions. A polymerase
chain reaction confirmed the presence of the toxin B gene,
tcdB in C. difficile isolates, which is defines the toxigenic
552 patients who were admitted to 
a medical ward
483 had stool samples collected for 
stool culture
347 had no C. difficile
isolated from stool
136 with C. difficile
isolated from stool
86 with toxigenic C.
difficile
50 with nontoxigenic  
C. difficile
14 developed C. difficile
-associated diarrhea 
72 remained asymptomatic 
fecal colonization
Figure 1. Results of screening for diarrhea patients with
toxigenic or nontoxigenic Clostridium difficile isolated from
stool samples.
Risk factors for Clostridium difficile-associated diarrhea 185C. difficile strain. All enrolled patients were followed until
discharge or death. The primary outcome was the occur-
rence of CDAD, and the secondary outcome was the crude
mortality rate at 60 days.
Information regarding demographic characteristics,
including tube feeding, co-morbidities, and antibiotic
exposure were obtained. The Charlson Comorbidity Index
was used to estimate the severity of underlying diseases.17Table 1 Clinical characters of 86 cases of fecal toxigenic Clo
C. difficile-associated diarrhea (CDAD) or not
Characters Total
n Z 86
Male sex 47 (54.7)
Age 73.6  13.7
Body weight, kg 49.9  11.4
Body mass index, kg/m2 19.4  3.8
Nasogastric tube feeding 47 (54.7)
Underlying diseases
Charlson Comorbidity Index 2.5  1.8
Hypertension 39 (45.3)
Diabetes mellitus 37 (43.0)
Stroke history 29 (33.7)
Chronic kidney disease 14 (16.3)
Congestive heart failure 10 (11.6)
Chronic obstructive pulmonary disease 9 (10.5)
Malignancy 9 (10.5)
Liver cirrhosis 1 (1.2)
Colonization duration, d 33.0  59.7
a Duration between the first and the last recognition of C. difficile
b Duration between the first recognition of C. difficile colonization
Data are n (%) of patients unless otherwise indicated.Chronic kidney disease (CKD) was defined as estimated
glomerular filtration rates (GFR) <60 mL/min/1.73 m2 for
at least 3 months.18 All antibiotics, steroids, H2 blockers,
and PPIs prescribed within 1 month before CDAD or at the
end of follow-up were recorded. Antibiotics were grouped
into the following classes: cephalosporins, fluo-
roquinolones, penicillins and b-lactamase inhibitor combi-
nations, carbapenems, glycopeptides, fosfomycin, and
metronidazole. Cephalosporins included cefazolin, cefur-
oxime, third-generation cephalosporins (ceftriaxone,
cefotaxime, or ceftazidime), and cefepime. Penicillins and
b-lactamase inhibitor combinations included piper-
acillinetazobactam and ampicillineclavulanic acid. Carba-
penems included imipenemecilastatin, meropenem, and
ertapenem. Glycopeptides were composed of vancomycin
and teicoplanin.
Diarrhea was defined as three loose stools within at least
a 2-day period. Toxigenic C. difficile colonization (tCDC)
was defined as patients with fecal tcdB-carrying C. difficile
in the absence of diarrhea. CDAD was defined as the pres-
ence of diarrhea without an alternative explanation and
tcdB-carrying C. difficile isolated in the feces. The tCDC
duration was defined as the period between the first
recognition of tCDC and the last recognition of tCDC or the
development of CDAD.
Statistical analysis was performed using statistical
software (SPSS, version 13.0). Continuous data were
expressed as means  standard deviations. The c2 test
was used for categorical variables, and the Student t test
for continuous variables. The factors with a p value <0.25
in the univariate analyses, and other factors that were
known to be associated with CDAD,19e21 were evaluated
by the multivariate regression model. A two-tailed p
value of <0.05 was considered to be statistically
significant.stridium difficile colonization who subsequently developed
No CDAD
n Z 72
CDAD
n Z 14
p
39 (54.2) 8 (57.1) > 0.99
73.6  14.1 73.4  11.7 0.96
50.7  11.4 46.5  10.7 0.21
19.7  3.9 18.1  3.1 0.16
36 (50.0) 11 (78.6) 0.05
2.4  1.9 3.0  1.1 0.11
34 (47.2) 5 (35.7) 0.62
27 (37.5) 10 (71.4) 0.04
22 (30.6) 7 (50.0) 0.22
11 (15.3) 3 (21.4) 0.69
8 (11.1) 2 (14.3) 0.66
9 (12.5) 0 0.34
8 (11.1) 1 (7.1) > 0.99
1 (1.4) 0 > 0.99
28.6  43.8a 55.6  110.5b 0.38
colonization.
and CDAD.
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During the 18-month study period, a total of 552 patients
were eligible for the study, and stool samples were ob-
tained from 483 patients within 48 hours of admission
(Fig. 1). Among the 483 patients, 136 (28.2%) had CDC.
Among patients who had CDC, 50 (10.4%) were excluded
because of nontoxigenic CDC. Thus, 86 (17.8%) patients
with tCDC were evaluated. Among those with tCDC, 47
(54.7%) were males with a mean age of 73.6 years. No
statistical difference in sex, age, body weight, or body mass
index, was found between the patients subsequently
developing CDAD and those remaining asymptomatic
(Table 1). Use of nasogastric tube feeding was noted in 47
(54.7%) patients with tCDC. The most common co-
morbidities found in patients with tCDC were hyperten-
sion (45.3%), diabetes mellitus (DM) (43.0%), and stroke
(33.7%).
Of the 86 patients, 14 (16%) developed CDAD, and 72
were still asymptomatic with colonization. Patients with
tCDC subsequently developing CDAD had a higher rate of
having DM and tube feeding compared to those that did not
develop CDAD. However, there was no difference in theTable 2 Medications during hospitalization in 86 cases of fecal
subsequent CDAD
Medications
Cephalosporins
Cefazolin, i.v.
Cefuroxime, i.v./o
Ceftazidime or ceftriaxone, i.v.
Cefepime, i.v.
Fluoroquinolones, i.v./o
Penicillins
Amoxicillin-clavulanic acid, i.v.
Piperacillinetazobactam, i.v.
Carbapenems, i.v.
Glycopeptides, i.v.
Fosfomycin, i.v.
Metronidazole, i.v./o
Two classes of antibiotics
Cephalosporin þ glycopeptide
Penicillin þ glycopeptide
Carbapenem þ glycopeptide
Cephalosporin þ penicillin
Cephalosporin þ carbapenem
Penicillin þ carbapenem
Three classes of antibiotics
Cephalosporin þ penicillin þ glycopeptide
Cephalosporin þ carbapenem þ glycopeptide
Penicillin þ carbapenem þ glycopeptide
Cephalosporin þ penicillin þ carbapenem
Proton pump inhibitors, i.v./o
H2-blockers, i.v./o
Steroids, i.v./o
Data are n (%) of patients unless otherwise indicated.
CDAD Z C. difficile-associated diarrhea; i.v. Z intravenous; o Z oraprevalence of other co-morbidities, such as CKD and ma-
lignancy, or in the Charlson Comorbidity Index between the
two groups. The duration from the first time of confirmed
colonization to CDAD was 55.6 days, which was longer than
the tCDC duration in patients who did not develop CDAD
(28.6 days), although the difference was not statistically
significant (p Z 0.38).
Regarding antibiotic exposure, patients with tCDC
developing CDAD were more likely to have prior exposure to
piperacillinetazobactam (p Z 0.03). There was no differ-
ence in prior use of third-generation cephalosporin, fluo-
roquinolones, carbapenems, glycopeptides, or fosfomycin
between the two groups. Furthermore, patients who once
received more than one class of antibiotics, such as a car-
bapenem plus a penicillin (p Z 0.01), a penicillin plus a
carbapenem plus a glycopeptide (p Z 0.03), or a cephalo-
sporin plus a penicillin plus a carbapenem, had a higher risk
of CDAD (Table 2). In the multivariate analysis the presence
of underlying DM (p Z 0.01), the administration of piper-
acillinetazobactam (p Z 0.04) or a carbapenem
(pZ 0.05), and the use of PPIs (pZ 0.04), were associated
with the development of CDAD (Table 3). Among the 14
patients with tCDC developing CDAD, 2 (14.3%) died withintoxigenic Clostridium difficile colonization with and without
No CDAD
n Z 72
CDAD
n Z 14
p
58 (80.6) 14 (100) 0.11
2 (1.7) 0 > 0.99
9 (12.5) 1 (7.1) > 0.99
43 (59.7) 10 (71.4) 0.55
22 (30.6) 7 (50.0) 0.22
3 (4.2) 1 (7.1) 0.52
22 (30.5) 5 (35.7) 0.76
14 (19.4) 0 0.11
8 (11.1) 5 (35.7) 0.03
22 (30.6) 7 (50.0) 0.22
18 (25.0) 4 (28.6) 0.75
3 (4.2) 1 (7.1) 0.52
1 (1.4) 0 > 0.99
32 (44.4) 6 (42.9) > 0.99
17 (23.6) 4 (28.6) 0.74
4 (5.6) 3 (21.4) 0.08
10 (13.9) 3 (21.4) 0.44
13 (18.1) 5 (35.7) 0.16
18 (25.0) 7 (50.0) 0.10
3 (4.2) 4 (28.6) 0.01
11 (15.3) 4 (28.6) 0.26
4 (5.6) 3 (21.4) 0.08
8 (11.1) 3 (21.4) 0.38
2 (2.8) 3 (21.4) 0.03
3 (4.2) 4 (28.6) 0.01
11 (15.3) 5 (35.7) 0.13
8 (11.1) 2 (14.3) 0.66
13 (18.1) 3 (21.4) 0.72
l.
Table 3 Multivariate analysis of risk factors for Clos-
tridium difficile-associated diarrhea in hospitalized adults
with toxigenic C. difficile colonization
Odds
ratio
95% confidence
interval
p
Diabetes mellitus 21.5 1.9e242.4 0.01
Stroke history 2.1 0.4e10.6 0.36
Nasogastric tube use 1.0 0.2e6.5 0.98
Body mass index 0.8 0.6e1.1 0.13
Piperacillinetazobactam use 17.4 1.2e249.5 0.04
Proton pump inhibitor use 10.1 1.2e87.4 0.04
Carbapenem use 5.5 1.0e28.7 0.05
Cefepime use 1.1 0.2e5.5 0.95
Risk factors for Clostridium difficile-associated diarrhea 18760 days, and 10 (13.9%) of 72 patients with CDC but who did
not develop CDAD died (p > 0.99).Discussion
In our earlier report, adult patients with tCDC had a higher
risk of developing CDAD in subsequent hospitalizations. In
the present study, we further identified three independent
risk factors of CDAD among hospitalized patients with tCDC:
The presence of underlying DM, recent use of piper-
acillinetazobactam, or PPIs. Such information is useful in
designing appropriate infection or antibiotic control mea-
sures to prevent CDAD when confronted with asymptomatic
adults with tCDC.
In our study, the exposure to piperacillinetazobactam
was associated with CDAD in patients with tCDC. Current
literature showed that exposure to several classes of anti-
microbial agents, including third-generation cephalosporins,
clindamycin, and fluoroquinolones, had been linked to
CDAD. To date, the influence of piperacillinetazobactam
exposure on the occurrence of CDAD is controversial. Mark
et al found that piperacillinetazobactam exposure was less
likely to induce CDAD,22 and Alston et al described an in-
crease in the rate of CDAD during the shortage of piper-
acillinetazobactam.23 In contrast, Marisa et al observed a
significant reduction in the rate of CDAD with reduced
availability of piperacillinetazobactam24 and Stevens et al
suggested that the receipt of penicillins and b-lactamase
inhibitor combinations, mainly piperacillinetazobactam,
was associated with an increased risk of CDAD.25 Likewise,
the debate of the role of piperacillinetazobactam exposure
among those with tCDC who develop subsequent CDAD re-
mains undefined. Settle et al showed a higher incidence of
CDAD in patients with CDC who were once treated with
cefotaxime (18/26, 69%) as compared to those treated with
piperacillinetazobactam (1/3, 33%).13 In our study, piper-
acillinetazobactam exposure was a predisposing factor of
CDAD in patients with tCDC. It is easy to critique that among
the above clinical studies, there is heterogeneity in terms of
the study population and concurrent exposure to medica-
tions other than the targeted antibiotics, and the method-
ology of detection of toxigenic C. difficile in stools, which
lead to contradictory interpretations of the interaction be-
tween prior exposure of piperacillinetazobactam and thedevelopment of CDAD. However, the animal experiments
conducted by Pultz et al, showing piperacillinetazobactam
facilitated overgrowth and toxin production by C. difficile in
mice,26 provide supporting evidence linking piperacilline
tazobactam therapy and CDAD.
Previous literature showed that individuals who had
received PPIs were at risk of CDAD. A meta-analysis re-
ported there was 65% increase in the incidence of CDAD
among patients taking PPIs.21 Another study found an odds
ratio of 1.74 for the occurrence of CDAD in those with prior
PPI use as compared with those without PPI exposure.27 It is
believed that PPI reduces gastric acidity, which in turn,
makes the pH levels greater than or equal to 5, and vege-
tative C. difficile can survive exposure to gastric con-
tents.28 However, this could not explain such a finding that
the patients with C. difficile presumably colonized in the
colon are susceptible to CDAD after PPI therapy. Since PPIs
affect gastric acidity, they may not alter the environment
of colon. However, there is evidence indicating that PPIs
decrease reactive oxygen production and bactericidal ac-
tivity of neutrophils,29 which mediate the defense activity
against C. difficile. Thus, we should be cautious regarding
the detrimental aspect of PPI therapy in predisposing sus-
ceptible individuals to the development of CDAD.
DM was another independent risk factor in patients with
tCDC to develop CDAD found in our study. Currently, the
issue that DM is a risk factor for CDAD remains controver-
sial. Some studies did not find the link between diabetes
and CDAD,30e33 but in a C. difficile outbreak in Costa Rica,
DM was recognized as an adjusted attributable risk for
CDAD.34 In addition, DM has been identified to be associ-
ated with severe CDAD35 or recurrent CDAD.36 Therefore,
clinicians should pay more attention to hospitalized dia-
betic patients, especially with tCDC, after their receipt of
antimicrobial therapy or PPIs because they are susceptible
to CDAD and subsequent complications.
Our study had several limitations. First, our study was
conducted in a hospital and included mainly the elderly
with underlying illnesses and those who recently received
antimicrobial therapy, and the representativeness was
limited due to the small sample size. Multicenter studies
involving more cases are needed to justify our findings.
However, this study was the first study to prospectively
observe the factors associated with CDAD among inpatients
with tCDC. Secondly, no genetic relatedness between the
colonized isolates and the isolates causing diarrhea was
investigated. Thus, the possibility of acquisition of another
C. difficile clone causing CDAD or the presence of a cluster
cannot be completely excluded. The clinical significance of
these risk factors will be changed given there is an unrec-
ognized cluster of CDAD. More studies will work on the issue
of genetic relationship.
In conclusion, our study showed that underlying DM and
prior use of piperacillinetazobactam or PPIs are the risk
factors of CDAD among hospitalized patients with tCDC.Conflicts of interest
The authors declare that they have no financial or nonfi-
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